396 related articles for article (PubMed ID: 11840265)
1. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors.
Plasilova M; Zivny J; Jelinek J; Neuwirtova R; Cermak J; Necas E; Andera L; Stopka T
Leukemia; 2002 Jan; 16(1):67-73. PubMed ID: 11840265
[TBL] [Abstract][Full Text] [Related]
2. Differential responses of myeloid progenitor cells from patients with myeloid leukemia and myelodysplasia to the costimulating effects of steel factor in vitro.
Maze R; Horie M; Hendrie P; Vadhan-Raj S; Tricot G; Gordon M; Nemunaitis J; Ashman LK; Broxmeyer HE
Exp Hematol; 1993 Apr; 21(4):545-51. PubMed ID: 7681784
[TBL] [Abstract][Full Text] [Related]
3. Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation.
Mizrahi K; Stein J; Pearl-Yafe M; Kaplan O; Yaniv I; Askenasy N
Leukemia; 2010 Jul; 24(7):1325-34. PubMed ID: 20485377
[TBL] [Abstract][Full Text] [Related]
4. Human recombinant interferon-inducible protein-10 inhibits the proliferation of normal and acute myelogenous leukemia progenitors.
Sarris AH; Talpaz M; Deisseroth AB; Estrov Z
Leukemia; 1996 May; 10(5):757-65. PubMed ID: 8656668
[TBL] [Abstract][Full Text] [Related]
5. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo purging of leukemia cells using tumor-necrosis-factor-related apoptosis-inducing ligand in hematopoietic stem cell transplantation.
Lee NS; Cheong HJ; Kim SJ; Kim SE; Kim CK; Lee KT; Park SK; Baick SH; Hong DS; Park HS; Won JH
Leukemia; 2003 Jul; 17(7):1375-83. PubMed ID: 12835727
[TBL] [Abstract][Full Text] [Related]
7. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
Wisniewski D; Strife A; Atzpodien J; Clarkson BD
Cancer Res; 1987 Sep; 47(18):4788-94. PubMed ID: 3040231
[TBL] [Abstract][Full Text] [Related]
8. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells.
Roodman GD; Bird A; Hutzler D; Montgomery W
Exp Hematol; 1987 Oct; 15(9):928-35. PubMed ID: 2820776
[TBL] [Abstract][Full Text] [Related]
10. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
[TBL] [Abstract][Full Text] [Related]
11. Expression and antitumor effects of TRAIL in human cholangiocarcinoma.
Tanaka S; Sugimachi K; Shirabe K; Shimada M; Wands JR
Hepatology; 2000 Sep; 32(3):523-7. PubMed ID: 10960444
[TBL] [Abstract][Full Text] [Related]
12. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis.
Zang DY; Goodwin RG; Loken MR; Bryant E; Deeg HJ
Blood; 2001 Nov; 98(10):3058-65. PubMed ID: 11698291
[TBL] [Abstract][Full Text] [Related]
13. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
[TBL] [Abstract][Full Text] [Related]
14. Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination.
Lemoli RM; Gulati SC; Strife A; Lambek C; Perez A; Clarkson BD
Leukemia; 1991 May; 5(5):386-91. PubMed ID: 1709711
[TBL] [Abstract][Full Text] [Related]
15. The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis.
Mace TA; Yamane N; Cheng J; Hylander BL; Repasky EA
Immunol Invest; 2006; 35(3-4):279-96. PubMed ID: 16916755
[TBL] [Abstract][Full Text] [Related]
16. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
[TBL] [Abstract][Full Text] [Related]
17. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak H; Miller RE; Ariail K; Gliniak B; Griffith TS; Kubin M; Chin W; Jones J; Woodward A; Le T; Smith C; Smolak P; Goodwin RG; Rauch CT; Schuh JC; Lynch DH
Nat Med; 1999 Feb; 5(2):157-63. PubMed ID: 9930862
[TBL] [Abstract][Full Text] [Related]
18. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
20. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Riccioni R; Pasquini L; Mariani G; Saulle E; Rossini A; Diverio D; Pelosi E; Vitale A; Chierichini A; Cedrone M; Foà R; Lo Coco F; Peschle C; Testa U
Haematologica; 2005 May; 90(5):612-24. PubMed ID: 15921376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
